DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES

Inicio / Programas UE / H2020 / IMI2-2016-09-02
Logo

(IMI2-2016-09-02) - DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES

Programme: Horizon 2020 Framework Programme
Call: H2020-JTI-IMI2-2016-09-two-stage EU

Topic description

Specific Challenge:

Autoimmune diseases affect approximately 5% of the population of Europe, with two-thirds of the patients being female.

Scope:

Development of a translational research project for the induction and monitoring of immune tolerance in Rheumatic Diseases: Rheumatoid Arthritis (RA).

Expected Impact:

If successful, immune tolerance approaches would revolutionize treatment of RA by inducing drug-free remission. Coupled with diagnostic tests, screening initiatives for “at-risk” individuals, it may stop the disease before joint damage can occur. For healthy but at-risk patient, this would offer a screening and “vaccination” for the prevention of RA.

Keywords

Biomarkers Public Private Partnerships (PPP) Diagnostic technology Immunological memory and tolerance Bioinformatics Medical pathology

Tags

New therapeutic agents New drug targets and pathways Diagnostic tests dendritic cells auto-antibody Immune tolerance OMICS Suppression of the immune response Autoantigens T cell response Bioinformatic analysis Development of biomarkers Inflammatory pathology Autoimmune diseases: Rheumatoid Arthritis Partnership Regulatory T-cell

Non atopas a financiación que precisas?

Contacta con nos e cóntanos cal é o teu proxecto.